ClinicalTrials.gov
public full text
Public Domain
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer#877642
- Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer#827553
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer#838105
- Docetaxel in Treating Patients With Stage IV Prostate Cancer#994703
- Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer#891811
Record · ID 859234
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive